CO2019008575A2 - Métodos para tratar infecciones bacterianas - Google Patents

Métodos para tratar infecciones bacterianas

Info

Publication number
CO2019008575A2
CO2019008575A2 CONC2019/0008575A CO2019008575A CO2019008575A2 CO 2019008575 A2 CO2019008575 A2 CO 2019008575A2 CO 2019008575 A CO2019008575 A CO 2019008575A CO 2019008575 A2 CO2019008575 A2 CO 2019008575A2
Authority
CO
Colombia
Prior art keywords
methods
bacterial infections
treat bacterial
urinary tract
tract infection
Prior art date
Application number
CONC2019/0008575A
Other languages
English (en)
Inventor
Michael N Dudley
Elizabeth E Morgan
David C Griffith
Jeffrey S Loutit
Karen Fusaro
Olga Lomovskaya
Original Assignee
Rempex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62791302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019008575(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rempex Pharmaceuticals Inc filed Critical Rempex Pharmaceuticals Inc
Publication of CO2019008575A2 publication Critical patent/CO2019008575A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen métodos para tratar o mejorar una infección del tracto urinario (UTI), que incluye infección del tracto urinario complicada (cUTI) y pielonefritis aguda (AP), que comprenden administrar una composición que comprende un éster de ácido borónico cíclico, vaborbactam, en combinación con meropenem.
CONC2019/0008575A 2017-01-09 2019-08-06 Métodos para tratar infecciones bacterianas CO2019008575A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444238P 2017-01-09 2017-01-09
US201762513936P 2017-06-01 2017-06-01
PCT/US2018/012839 WO2018129479A1 (en) 2017-01-09 2018-01-08 Methods of treating bacterial infections

Publications (1)

Publication Number Publication Date
CO2019008575A2 true CO2019008575A2 (es) 2019-08-30

Family

ID=62791302

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0008575A CO2019008575A2 (es) 2017-01-09 2019-08-06 Métodos para tratar infecciones bacterianas

Country Status (17)

Country Link
US (1) US20190336475A1 (es)
EP (2) EP3565551B1 (es)
JP (2) JP7436206B2 (es)
KR (1) KR20190104385A (es)
CN (1) CN110402139A (es)
AU (1) AU2018205327B2 (es)
BR (1) BR112019014089A2 (es)
CA (1) CA3048650A1 (es)
CL (2) CL2019001918A1 (es)
CO (1) CO2019008575A2 (es)
DK (1) DK3565551T3 (es)
FI (1) FI3565551T3 (es)
MX (2) MX2019008281A (es)
NZ (1) NZ755141A (es)
PH (1) PH12019501606A1 (es)
SG (1) SG11201906226YA (es)
WO (1) WO2018129479A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202003009QA (en) 2017-10-03 2020-04-29 Melinta Therapeutics Inc Methods of treating bacterial infections
WO2024018372A2 (en) * 2022-07-20 2024-01-25 Sri Sathya Sai Institute Of Higher Learning A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
EP3666778B1 (en) 2010-08-10 2021-11-10 Melinta Therapeutics, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014186309A1 (en) * 2013-05-15 2014-11-20 Schaeffler Technologies Gmbh & Co. Kg Reduced drag clutch plate
CN112755039A (zh) * 2015-04-24 2021-05-07 莱姆派克斯制药公司 治疗细菌感染的方法

Also Published As

Publication number Publication date
NZ755141A (en) 2023-01-27
JP2023012538A (ja) 2023-01-25
WO2018129479A1 (en) 2018-07-12
JP7436206B2 (ja) 2024-02-21
MX2022001704A (es) 2022-03-11
JP2020504154A (ja) 2020-02-06
DK3565551T3 (da) 2024-06-17
EP3565551B1 (en) 2024-03-20
EP4212157A1 (en) 2023-07-19
EP3565551A1 (en) 2019-11-13
CL2020001886A1 (es) 2020-12-18
CA3048650A1 (en) 2018-07-12
EP3565551A4 (en) 2020-09-23
SG11201906226YA (en) 2019-08-27
AU2018205327A1 (en) 2019-07-25
PH12019501606A1 (en) 2020-06-15
AU2018205327B2 (en) 2023-11-30
US20190336475A1 (en) 2019-11-07
KR20190104385A (ko) 2019-09-09
FI3565551T3 (fi) 2024-06-18
BR112019014089A2 (pt) 2020-02-04
CL2019001918A1 (es) 2020-02-14
MX2019008281A (es) 2019-12-02
CN110402139A (zh) 2019-11-01

Similar Documents

Publication Publication Date Title
MX2016009898A (es) Tratamientos para acne resistente.
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
BR112017025813A2 (pt) método, kit ou composição, micróbio comensal benéfico, método para tratar ou prevenir o câncer e formulação bacteriana
EA201591761A1 (ru) Композиции на основе наночастиц
FR2969495B1 (fr) Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
BR112014008819A2 (pt) métodos para o tratamento de síndrome de vazamento vascular e câncer
TW201613575A (en) Treatment of polybacterial infections
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
CO7141430A2 (es) Formulaciones vesiculares para uso en el tratamiento del dolor o movilidad reducida de una articulación
CO2019008575A2 (es) Métodos para tratar infecciones bacterianas
BR112017018963A2 (pt) método para tratar anemia por deficiência de ferro
WO2014152437A3 (en) Methods of use for an antimicrobial peptide
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
EA202191631A1 (ru) Композиции, содержащие бактериальные штаммы
IN2013MU03216A (es)
CL2012003202A1 (es) Metodo para tratar una infeccion gastrointestinal recurrente de clostridium difficile, que comprende la administracion de fidaxomicina y donde el sujeto ha sido sometido a un tratamiento previo para combatir dicha infeccion.
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
AR104200A1 (es) Carboximetilcisteina para tratamiento tópico de estrías
RU2014125665A (ru) Способ наружного лечения микозов кожи
EA201591267A1 (ru) Рифаксимин для применения в лечении вагинальных инфекций
UA112075C2 (uk) Виділений екстракт з рослини ficus arnottiana
AR109025A1 (es) Composiciones que comprenden cepas bacterianas